Key Points:
- Salvo Health, a digital healthcare startup based in New York, has closed a $5 million Seed Prime funding round led by City Light Capital and Human Ventures.
- Existing investors, including Torch Capital, Threshold Ventures, and Felicis Ventures, along with angel investors such as Anmol Madan, also participated in the funding round.
- Emily Melton of Threshold, Rachel Parlier of City Light Capital, and Salvo’s founder and CEO Jeffrey Glueck will join the company’s board of directors.
- Salvo Health offers a virtual clinic specializing in chronic gastrointestinal and metabolic liver issues, catering to conditions like celiac disease, fatty liver disease, irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), small intestinal bacterial overgrowth (SIBO), and dyspepsia.
- The company provides “wraparound care,” allowing patients to maintain their local physician while accessing Salvo’s app-based support. Patients are matched with a care team comprising registered dietitians, behavioral health specialists, and licensed nurses, enabling them to receive insurance-covered interdisciplinary care.
- The funding will be used to scale Salvo’s wraparound GI services to providers, including accountable care organizations, gastroenterology private practices, and health systems.
- Rachel Parlier of City Light Capital emphasized Salvo’s potential to transform industries and improve lives, particularly by addressing the gaps in care for underserved patient populations.
Market Snapshot:
- Salvo Health was founded in 2022 with $10.5 million in funding to expand its virtual clinic for chronic GI conditions.
- Competitors in the virtual digestive care space include Vivante Health, which secured $31 million in funding in September, and Oshi Health, which raised $30 million in Series B funding in April.
Salvo Health aims to enhance access to high-quality gastrointestinal care through its innovative virtual clinic model, addressing the needs of patients with chronic digestive conditions.